Ohr Pharmaceuticals (NASDAQ: OHRP) is one of 93 public companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Ohr Pharmaceuticals to similar companies based on the strength of its risk, dividends, profitability, institutional ownership, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Ohr Pharmaceuticals and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ohr Pharmaceuticals 0 1 1 0 2.50
Ohr Pharmaceuticals Competitors 163 542 1199 16 2.56

Ohr Pharmaceuticals presently has a consensus price target of $10.00, suggesting a potential upside of 1,210.62%. As a group, “Biotechnology” companies have a potential upside of 55.19%. Given Ohr Pharmaceuticals’ higher possible upside, research analysts clearly believe Ohr Pharmaceuticals is more favorable than its competitors.

Valuation and Earnings

This table compares Ohr Pharmaceuticals and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Ohr Pharmaceuticals N/A -$24.22 million -1.09
Ohr Pharmaceuticals Competitors $223.74 million $57.84 million -0.65

Ohr Pharmaceuticals’ competitors have higher revenue and earnings than Ohr Pharmaceuticals. Ohr Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


This table compares Ohr Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ohr Pharmaceuticals N/A -103.56% -85.09%
Ohr Pharmaceuticals Competitors -917.30% -187.05% -24.43%

Insider & Institutional Ownership

7.0% of Ohr Pharmaceuticals shares are held by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are held by institutional investors. 17.4% of Ohr Pharmaceuticals shares are held by company insiders. Comparatively, 20.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Ohr Pharmaceuticals has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Ohr Pharmaceuticals’ competitors have a beta of 1.14, indicating that their average stock price is 14% more volatile than the S&P 500.


Ohr Pharmaceuticals competitors beat Ohr Pharmaceuticals on 9 of the 12 factors compared.

About Ohr Pharmaceuticals

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

Receive News & Ratings for Ohr Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.